Summary:
A Phase 2 study to investigate the efficacy, safety, and tolerability of six weeks treatment with V565 in subjects with active Crohn’s disease
Qualified Participants Must:
• 18 to 80 years old
•
History or diagnostics of Crohn's disease
•
No other significant diseases (No cancers, heart failures, kidney failure and so on)
Qualified Participants May Receive:
Reimbursement for travel and time.
Free lab tests.
Free conloscopy.
Free examination.
Free hotels or accomodations if needed.